Late Stage and Commercial Development
The large-scale Agilent facility in Frederick produces multikilogram lots of oligo APIs for late-stage clinical trials and commercialization. To increase batch sizes and accommodate more programs, Agilent launched a second manufacturing train in 2023. Future expansion is additionally planned for 2027.